The Use of Quinacrine in Nitroimidazole-Resistant Giardia
                Duodenalis: An Old Drug for an Emerging Problem by Requena-Méndez, Ana et al.
Ac
ce
pt
ed
 M
an
us
cr
ipt
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All 
rights reserved. For permissions, e-mail journals.permissions@oup.com. 
THE USE OF QUINACRINE IN NITROIMIDAZOLE-RESISTANT GIARDIA 
DUODENALIS: AN OLD DRUG FOR AN EMERGING PROBLEM 
Ana Requena-Méndez
1
, Pilar Goñi
2
, Encarnación Rubio
2
, Diana Pou
3
, Victoria 
Fumadó
4
, Silvia Lóbez
2
, Edelweiss Aldasoro
1
, Juan Cabezos
3
, Maria Eugenia 
Valls
5
, Begoña Treviño
3
, Antonio Federico Martínez Montseny
4
, Antonio Clavel
2
, 
Joaquim Gascon
1
, José Muñoz
1
. 
1. Barcelona Institute for Global Health (ISGlobal-CRESIB, Universitat de 
Barcelona) 
2. Department of Microbiology, Preventive Medicine and Public Health. 
Faculty of Medicine. University of Zaragoza, Zaragoza, Spain 
3. Unidad de Salud Internacional Drassanes-Hospital Universitario Vall 
d'Hebron. PROSICS, Barcelona 
4. Unitat de Malalties Infeccioses i Importades. Servei de Pediatría. Infectious 
and Imported Diseases, Paediatric Unit. Hospital Universitari Sant Joan de 
Deú 
5. Department of Microbiology. Hospital Clínic, Barcelona, Spain. 
Key words: refractory giardiasis, Giardia, treatment, nitroimidazole, PCR, 
quinacrine, tpi gene, bp gene, genetic characterization 
 
 
  
Ac
ce
pt
ed
 M
an
us
cr
ipt
 
 
SUMMARY: 
The study describes an almost 20% prevalence of imported refractory giardiasis 
diagnosed in 3 Tropical-Medicine Units in Barcelona, shows a 100% efficacy rate 
of quinacrine in nitroimidazole-refractory cases and compares genetic 
characteristics of Giardia cases. 
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ABSTRACT 
BACKGROUND: There is little evidence in the management of refractory 
giardiasis after treatment with nitroimidazoles. This study estimates the proportion 
of persistent giardiasis in 3 hospitals in Barcelona, describes risk factors and 
genotype associated and evaluates the efficacy rate of quinacrine in those with 
persistent giardiasis.  
METHODS: A clinical prospective observational study was conducted in patients 
with giardiasis treated with nitroimidazoles. Those with persistent giardiasis were 
provided quinacrine. Molecular characterization of Giardia isolates was performed 
by PCR amplification of a fragment of tpi and bg genes.   
RESULTS: Seventy-seven patients were recruited and treated with nitroimidazoles 
and in 14/71 of patients followed-up(20%), Giardia persisted. Refractory 
giardiasis was associated with malaise(p:0.007) and anorexia(p:0.019), with 
previous giardiasis(p:0.034) and with previous antibiotic(p:0.02) or 
antiparasitic(p:0.037). Quinacrine had an effectiveness rate of 100% in refractory 
giardiasis(n=13,95%CI 75-100). 
Molecular characterization showed that 17(25%) Giardia isolates belonged to 
assemblage A, 31(43%) to assemblage B. In refractory giardiasis, assemblage B 
and A were found as responsible in 6 and 4 cases respectively. 
CONCLUSIONS: Almost 20% of patients presented persistent giardiasis after 
nitroimidazole being both assemblage A and B involved. Short course of 
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quinacrine was effective in treating refractory cases and further controlled studies 
should evaluate its efficacy and safety. 
INTRODUCTION 
Giardia duodenalis is one of the most common intestinal parasitic protozoa 
reported in humans(1).  The protozoon is distributed worldwide(2,3) and estimates 
indicate that more than billion people  are at risk of giardiasis infection. It is much 
more prevalent in developing countries due to its association with poverty(4) 
where water contaminated with G.duodenalis cysts frequently causes travelers-
related giardiasis(5). In industrialized countries, the infection is re-emerging(6) 
causing waterborne and to a lesser extent food-borne outbreaks(6,7).  
Symptoms range from asymptomatic infection to mild and chronic diarrhea(8,9) 
The causes to explain the variability of symptoms remain unclear although 
multiples factors have been proposed. Some findings suggest that age and previous 
Giardia exposure are associated with mucosal inflammation and the intensity of 
symptoms(10). Geographic and population variation can also affect the host 
immune response against G.duodenalis(11). Genetic variability of Giardia strains 
has been also suggested to influence the simptomatology of the disease, although 
no association has been found between Giardia genotypes (assemblage A and B) 
and clinical symptoms when comparing different studies(1,12).  
PCR-techniques , in addition to providing excellent sensitivity and specificity 
compared with microscopy and antigen detection methods(13–15), have being 
extremely useful in recent years to improve knowledge and understanding of 
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G.duodenalis genetics. Application of these techniques to characterize the Giardia 
isolates responsible for cases of refractory giardiasis has identified the assemblage 
B as responsible for these cases worldwide. To our knowledge, there have been no 
reports of refractory giardiasis produced by Giardia assemblage A. However, not 
all reported cases have been typed and the limited number of those studied makes 
it difficult to establish a definitive association between assemblage and resistant 
giardiasis.  
Persistence of giardiasis despite nitroimidazole therapy is also relatively common 
in patients with chronic giardiasis accounting for about 20% of cases(16). This 
may be due to re-infection, immunosuppression or drug resistance(17).  There is no 
standardized second-line regimen for refractory giardiasis. A second course of 
nitroimidazoles given for several consecutive days, and changing the type of 
antiparasitic agent and combination therapy have been tested in these cases(17). 
Quinacrine has been reported to have high efficacy-rate to treat giardiasis(1) 
although it has been associated with severe side-effects and poor adherence. In a 
previous retrospective study we demonstrated a 100% efficacy rate in patients 
treated with this drug using 7-day short course regimen, which was not associated 
with severe adverse effects(5).  
This study aims to estimate the proportion of nitroimidazole-resistant G.duodenalis 
in the population attending three Tropical Medical Units and attempt to describe 
the risk factors and the assemblages associated with the persistence of giardiasis. 
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Further, the effectiveness of quinacrine in the treatment of these patients with 
resistant giardiasis is assessed.  
 
METHODS 
Study design, participants, and setting. 
A prospective observational study was conducted in 3 specialized Tropical 
Diseases Units in Barcelona, Spain. From July-2012 to July-2013, all patients 
diagnosed with G.duodenalis attending the Tropical Medicine Unit (TMU) from 
Hospital Clinic, TMU-Drassanes and Hospital Sant Joan de Deu in Barcelona were 
invited to participate in the study.  Patients unwilling or unable to give informed 
consent were excluded. For 95% of confidence level and a 20% of refractory 
giardiasis established by previous studies(16), considering a total of 71 patients, 
the final precision obtained was 10%.  Participants were interviewed using a 
semistructured questionnaire. Particular emphasis was put on previous travel 
during the last 6 months, detecting previous gastrointestinal diseases, and other 
factors that could contribute to malabsorption. Gender, age, height (cm) and weight 
(kg) were recorded. All patients provided a stool sample before they were treated. 
Standard formalin-ether concentration of all the stool samples was 
microscopically examined for the presence of Giardia cysts or trophozoites. 
In addition, an immunocromatography test was performed in fresh samples 
with the Stick Giardia test (Stick Giardia antigen kit, Operon SA). The 
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combined use of these two techniques  aimed to achieve a greater sensitivity 
for those cases with low number of cysts and to minimize the possibility of 
obtaining false negatives. All patients were initially treated with 
nitroimidazoles (adults and children aged >5 years with tinidazole 2g, one day 
and children aged <5 years, with metronidazole 30mg/Kg/day, 7 days). Two 
control stool samples were collected and analyzed by microscopy and 
immunochromatography (IC) 30 days (+/-10 days) after treatment. Those 
infections with confirmed persistence of G.duodenalis (by detection of cysts 
in fecal samples or by IC were defined as refractory giardiasis and were 
subsequently treated with quinacrine at a dose of 100mg tid, 5 days. In 
children, the dose was adjusted to 8mg/Kg/day,  5 days.  
 Other routine tests such as stool cultures, microscopic observation or parasitic 
serologies were conducted to investigate the presence of other intestinal 
agents that may cause intestinal symptoms. HIV and IgA deficiency tests were 
performed in those patien s diagnosed with refractory giardiasis. 
 
Molecular characterization 
An aliquot of all fecal samples was refrigerated and sent to the University of 
Zaragoza where further molecular analysis was undertaken. Previous to DNA 
extraction, a treatment of samples was performed in order to improve DNA 
quality. Giardia cysts were purified and concentrated using a sucrose gradient 
flotation method.  Thereafter, cysts underwent 5 cycles of freezing (at -80 ° C, for 
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30 minutes) - defrosting (at 100 °C, for 10 minutes) and a final treatment with 
proteinase K (final concentration 100 µg/ml, overnight). When no cysts were 
observed, fresh stool samples were given the same pre-treatment with a sucrose 
gradient flotation method. DNA extraction was carried out after digestion of cysts 
or fresh samples using a commercial kit (Stool DNA Isolation Kit, Norgen Biotek 
Corp., Ontario, Canada) following the manufacturer's instructions. 
G.duodenalis assemblage was determined by Polymerase Chain Reaction (PCR) of 
the triosephosphate isomerase (tpi) and ß-giardin (bg) genes following the 
protocols described by Sulaiman et al.(18) and Lalle et al.(19) respectively. PCR 
products were purified with GFXTM-PCR-DNA Gel Band Purification Kit (GE 
Healthcare) and then directly sequenced in both directions. The nucleotide 
sequences obtained were analyzed using BioEdit program (BioEdit sequence 
alignment editor, copyright @ 1997-2013 Tom Hall; Ibis Biosciences, 
Carlsbad,CA; URL:http://www.mbio.ncsu.edu/bioedit/bioedit/html) and they were 
compared with the sequences deposited in GenBank.  
The DNA sequences obtained have been deposited in the Genetic sequence 
database at the National Center for Biotechnical Information (NCBI) under 
accession numbers JQ782391-JQ782407 and KX468980-Kx469069 
Statistical methods   
Data were double entered into an EpiData database; checked with EpiData 
software, version 3.1; and analyzed with STATA, version 13. 
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Statistical analysis 
For numerical variables a normal distribution was tested with the Shapiro-Wilk 
normality test. As they did not follow a normal distribution, they were expressed as 
median (interquartile range –IQR) and were compared with unpaired Kruskal 
Wallis test.  
Categorical variables were described with the number and percentages. They were 
compared using Monte Carlo and Fisher Exact test. To show the relation between 
patients with or without persistence of G. duodenalis and the rest of variables, OR 
and 95% confident interval were calculated 
A backwards stepwise multivariate logistic regression analysis was performed to 
assess the variation of refractory giardiasis. Independent variables of the model 
were considered those that showed a p<0.2 with refractory giardiasis in the 
bivariate analysis.  The goodness-of-fit of this model was calculated using means 
of the Hosmer-Lemeshow test, requiring a value of p>0.05.  To avoid possible 
multicollinearity problems, it was required to have a variance inflation factor < 5 in 
all coefficients of the final model. The Odds Ratio with a confidence interval of 
95% was used as the main estimator obtained from the statistical analyses(20). 
 Ethics: The study protocol and consent form were approved by the ethics 
committee of Hospital Clínic and Sant Joan de Deu Hospital and the ethic 
committee of Gol–i-Gurina. 
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RESULTS 
General characteristics of the patients 
Seventy seven patients were included in the study, 41(53%) were male and 22(29) 
were children (<18 years old). Twenty one(27%) were immigrants, 7(9%) were 
“visiting friends & relatives” (VFR), and 41 (53%) were tourist or worker travelers 
who had visited endemic countries. Eight patients (10%) had not travelled outside 
Spain in the previous six months. Patient characteristics by the geographic area 
where the infection was most probably acquired are summarized in Table 1.  In 
almost half of the patients (37), Giardia was acquired in Asia (75% of these 
patients had visited the Indian subcontinent), 26% in Africa, 14% in Latin-America 
(LA) and 12% in Europe. Travelers were the most frequent group for giardiasis 
acquired in Asia (81%) whereas immigrants were more predominant for giardiasis 
from LA (55%) and from Africa (40%)  and autochthonous patients (89%) in 
giardiasis acquired in Europe (p<0.001).   
Most patients reported at least one risk factor for Giardia acquisition.  Sixty-eight 
per cent of patients had consumed raw salad or raw meat and 60% of patients 
drank tap water in some occasions although this percentage was higher in people 
that had been in LA or Africa compared to Asia (p< 0.001). Tap water 
consumption during travel was also more frequent in migrants (82.35%) and VFR 
(85.71%) than travelers (55%),(p= 0.02).  
Around a third of patients had been working with patients (hospitals, day-care 
centres, nurseries…) and 4% had a previous episode of giardiasis. 
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Only eight patients (11%) were asymptomatic and this was more frequent in 
migrants (p= 0.018). Asymptomatic patients were more frequent in participants 
coming from LA, followed by Africa and Asia (p=0.009). In autochthonous 
infections, all patients were symptomatic. Having fever, abdominal pain, vomiting, 
weight loss or malaise were more frequent in patients coming from Asia (p= 0.004, 
p= 0.001, p= 0.005, p= 0.036, p= 0.01 respectively). 
 The following co-infections were observed: E.histolytica/dispar (5), Ascaris 
lumbricoides(2),    Strongyloides stercoralis(3),    Trichuris trichiura(1),    
Blastocystis hominis(3)   Schistosoma spp.(2), Cryptosporidium spp.(1), and 
Salmonella spp.(1). However, persistence of giardiasis was not associated with 
having other concomitant intestinal parasitic infections. For each individual, we 
also calculated the number of risk factors for Giardia acquisition and the number 
of any other intestinal parasites. No statistically significant differences were found 
in the distribution of these variables in the geographic areas analyzed (see table 
1)”.    
Refractory giardiasis 
All patients were treated either with tinidazole, or in the case of children, 
metronidazole. Seventy-one patients had further followed-up after the initial 
treatment, and 20 of them (28%) were remained symptomatic. In 14 patients (20%; 
CI95% 11-29), G.duodenalis was found in the stool analysis. In the univariate 
analysis, the persistent giardiasis was more frequent when the infection was 
acquired in Asia (10/35, 29%) compared to Africa (3/18, 17%), America (1/11, 
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9%) or Europe (0/7, 0%) but this association was not statistically significant (p= 
0.23). 
Out of the three HIV patients, two were cured after tinidazole treatment and one 
was lost to follow-up. Refractory giardiasis was associated with systemic 
symptoms (malaise, p= 0.014 and anorexia, p= 0.049), and as expected, with 
previous antibiotic (p= 0.033). A relevant association was also found, although not 
statistically significant, between refractory giardiasis and having traveled to Asia 
(p=0.079), suffering diarrhea (0.090), having suffered previous giardiasis 
(p=0.094) and having been treated with antiparasitic (p= 0.097) (See Table 2).  
Neither the initial treatment for giardiasis provided (metronidazole vs. tinidazole), 
the origin of Giardia acquisition, nor having severe symptoms was significantly 
associated with the persistence of Giardia in our model. According to the 
multivariate analysis, the risk of suffering refractory giardiasis is higher in patients 
with malaise (OR=5.02 CI=1.09-23.03), previous treatment (antiparasitic and/or 
antibiotic) (OR=6.19 CI=1.41-27.14) and in men (OR=2.85 CI=0.65-12.43) (See 
Table 3). 
 
Following the study protocol, 13 patients with persistent giardiasis took quinacrine 
and tinidazole was prescribed for one child who had previously taken 
metronidazole. He was the only participant in whom G.duodenalis persisted 
despite the drug treatments, and clinically improved and was cured only after 
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receiving quinacrine in a third line course of treatment. Another child completed 
only 3 out of 5 days of quinacrine therapy due to adverse events, presenting 
irritability and somnolence that disappeared after stopping the treatment. However, 
Giardia was not found in subsequent serial stool examinations and he was 
considered cured.  
 Giardia analysis and characterization 
Molecular analysis was conducted for 76 patients. A total of 105 sequences from 
54 patients were obtained. Amplification was positive for 58 samples from 40 
patients where tpi gene was analyzed and for 47 samples from 39 patients where 
the bg gene was analyzed. Amplification of the two genes simultaneously was 
positive for only 24 samples from 20 patients. The predominant genotype was 
assemblage B in 31 patients (42%) followed by A in 17 (25%) patients. A mixed 
infection by the two assemblages was observed in six patients and no amplification 
despite the observance of cysts was observed in 18 (25%). Negative PCR test was 
observed in 5 cases (7%). 
Notably, out of 44 non refractory cases, 15 were PCR positive one month after the 
antiparasiti  therapy (12 presented Giardia assemblage B, 2 assemblage A and 1 
was a mixed infection A+B); although only three of them were still symptomatic. 
These non-refractory cases were followed during one month after treatment as 
planned.  
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For the 14 patients with persistence of Giardia cyst in stool examinations after 
nitroimidazole therapy (thirteen symptomatic and one asymptomatic), 6 of them 
presented Giardia assemblage B (5 Asia-acquired cases, 1 LA-acquired case). 
Three cases had an assemblage A (2 Africa-acquired cases, 1 Asia-acquired case) 
and in 4 cases there was no amplification and the PCR-test resulted negative. A 
specific assemblage was not associated with the persistence of Giardia (p>0.05). 
Homology of sequences of different samples of the same patient ranged between 
97 to 100% for assemblage B (analyzed by amplification of tpi gene), and had 
100% homology for those of assemblage A. When comparing sequences of bg 
gene, there were not any single nucleotide polymorphims (SNP). However, 
identity among sequences from different patients and different geographical 
locations was observed. One month after quinacrine therapy, all 14 patients 
improved clinically and fecal antigen detection and stool examinations were 
negative but PCR was still positive in 3 cases. Two of them were further followed 
up during two months and they were still positive for at least for 2 months after the 
quinacrine therapy. Both these patients belonged to assemblage B. 
DISCUSSION  
This work highlights an elevated proportion of refractory giardiasis after treatment 
with nitroimidazoles. It observed in almost 20% of patients treated with 
nitroimidazoles, which is similar to the reported efficacy of 80-90% 
elsewhere(17,21,22).  Our study was not able to demonstrate any statistically 
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significant association with refractory giardiasis and the acquisition of giardiasis in 
Asia, as it has been reported elsewhere(16,23).  
The differences in treatment failure among geographic areas could be attributable 
to acquired drug resistance, explained by several mechanisms. First, it has been 
proposed that that there is a geographical distribution of Giardia assemblages 
around the world although a particular assemblage of G. duodenalis has not been 
demonstrated to be associated with refractory giardiasis(24). In our study, 
assemblage B was predominant in refractory cases, consistent with other 
reports(25), although the study lacked the statistical power to demonstrate this 
effect. However, to our knowledge only cases of refractory giardiasis produced by 
Giardia belonging to assemblage B have been described. Therefore, this work is 
the first to describe refractory giardiasis by Giardia assemblage A, proving its 
plausibility and suggesting the importance of carrying out the molecular 
characterization of Giardia populations concerning refractory giardiasis. 
Second, since the levels of drug pressure may be variable in different parts of the 
world where G. duodenalis is endemic, this could also be a key factor in the 
development of drug resistance in Giardia strains(26). 
 Being a traveler or a migrant was significantly associated with the geographic 
origin where the Giardia was acquired.  Accordingly, for most travelers, Giardia 
was acquired when travelling to Asia, particularly to India, whereas for migrants, 
the geographic origin of Giardia was mainly either Africa or Latin-America. These 
findings could be explained because in the three sites where the study was carried 
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out, more than 40% of travelers go to Asia and migrants are predominantly coming 
from Africa and Latin-America (unpublished data).  
Our data are in concordance with other published data of imported giardiasis in 
which the risk of giardiasis in returning traveler was higher in the Indian 
Subcontinent and Arab countries(27). Although our study could not demonstrate 
that giardiasis acquired in Asia is more likely to be refractory to first-line therapy, 
a greater proportion of refractory giardiasis was found in cases coming from this 
continent compared to the other regions. 
Having severe symptoms such as malaise or anorexia before initial therapy, was 
associated with refractory giardiasis, and could be suggestive of higher parasitic-
load infections. If this could be demonstrated,  in these cases it could be considered 
to offer another treatment scheme, such as  multiple-dose of nitroimidazoles(1). 
The evaluation of treatment efficacy in G.duodenalis cases is rather complicated 
using the current diagnostic methods.  PCR could be helpful to identify low 
parasitic load infections. However, our data suggest that almost 35% of patients 
presented positive PCR despite being considered cured according to the clinical 
and stool-tests findings; which is an unexpectedly high percentage compared with 
other studies that show a 100% of negativization of PCR one week after a 3-day 
course of metronidazole therapy(28).   One possible explanation is that PCR 
sensitivity may be higher due to the molecular techniques undertaken for the 
genotypic characterization (in our study several PCR tests have been undertaken in 
the same sample what may have increased the global sensitivity). On the other 
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hand, as it has been reported by Martinez-Gordillo et al, the intraepithelial 
presence of a low number of Giardia trophozoites is possible, resulting in a 
positive PCR(29).  Additionally, the variability obtained for sequences of tpi gene 
and the low variability of bg gene raises questions about what differences are there 
among Giardia assemblages and the usefulness of genotyping methods for their 
characterization. The significance of these results should be clarified in future 
studies. 
Quinacrine demonstrated a 100% effectiveness rate, as has been previously 
described(5,30,31), and only one case of adverse events was observed which led to 
stop the treatment. This case was a child weighting less than 10Kg, making the 
optimal dose difficult to obtain due to a lack of pediatric formulation of quinacrine. 
However, even with a shorter 3-days regimen, quinacrine was effective to eradicate 
the parasite.  
Thus, quinacrine should be considered as a second line drug treatment when 
available. Quinacrine is currently a medicinal product on a compassionate-
use basis and therefore advocacy is needed to include giardiasis as one of its uses.  
However, more controlled studies such as randomized trials are required to better 
evaluate the efficacy rate of quinacrine for giardiasis and particularly to monitor its 
potential side effects.   
Besides the skin discoloration that has been reported, one of the main concerns 
when prescribing quinacrine is the occurrence of psychiatric adverse events 
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particularly in those people predisposed(32). In an study conducted during the 
Second World War in 7604 patients with malaria, quinacrine was shown to induce 
psychosis in 0.46% of patients(33). However, the mean total cumulative dose was 
2100mg, which is higher than the 1500mg total dose recommended in our study. 
Moreover, the role of pre-existing malarial infection and previous combat 
experience that could have contributed to the clinical spectrum of the psychiatric 
disorders was not properly evaluated. Another prospective case series reported 
evidence of pronounced psychological  stimulation in five  cases after quinacrine 
administration with cumulative dose in the first day of 1200mg and a total 
cumulative dose higher than 4000mg; proving that quinacrine acts as a cortical 
stimulant(34).  All patients had a rapid resolution of symptoms and there were no 
permanent sequelae noted. Finally, another more recent prospective study 
described neurologic and psychiatric adverse events  in three patients with 
refractory giardiasis treated with quinacrine in combination with metronidazole, 
but again all patients were treated at a dose of 100mg t.i.d for 3 weeks which is 
equivalent to a cumulative dose of more than 6300mg(35) much higher than the 
dose recommended in our study. Another clinical trial conducted in children 
comparing mebendazole vs. quinacrine for the treatment of giardiasis, adverse 
events were frequently described in those treated with quinacrine. However, all 
adverse events were graded as mild, they did not affect the central nervous system 
nor warrant the discontinuation of the treatment in any patient(36). 
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In our study, all patients were cured with a 5-days schedule at a dose of 100mg tid. 
Only one of 14patients suffered an adverse event that caused discontinuation of the 
therapy. The patient was an 11-month-old baby that presented irritability and 
sleeplessness and it was not possible to evaluate the existence of a neuropsychiatric 
disorder.  Further controlled studies are warranted to evaluate the efficacy and also 
the adverse effects of 3-5 days regimens of quinacrine.  
CONCLUSIONS 
Almost 20% of patients presented persistence of giardiasis despite nitroimidazole 
therapy. This outcome was not associated with a particular assemblage, as Giardia 
assemblage B was predominant, but some cases produced by Giardia assemblage 
A were observed. Short-course of quinacrine had 100% effectiveness although the 
optimal dosage remains unknown and the drug has not been approved to be used in 
giardiasis. Randomized controlled trials are needed to evaluate efficacy and safety 
of quinacrine as a second line therapy. Finally, PCR may persist positive in 
asymptomatic patients apparently cured according to clinical and stool test criteria.  
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Table 1. Participants characteristics by subgroup 
 Continent p-
valu
e 
Total 
(77) America 
(11) 
Asia 
(37) 
Africa 
(20) 
Europe 
(9) 
Sex (male) 5 (46) 17 (46) 13 (65) 6 (67) 0.4 41 
(53) 
Age  
    0-18 
    19-34 
    35 maximum 
 
2(18) 
6(55) 
3(27) 
 
4(11) 
18(49) 
15(41) 
 
9(45) 
3(15) 
8(40) 
 
7(88) 
1(13) 
0(0) 
 
<0.0
01 
 
22(29
) 
28(37
) 
26(34
) 
Patients 
   Migrants 
   Travelers 
   VFR* 
   No travel 
 
6(545) 
4(36) 
1(9) 
0(0) 
 
6(16) 
30(81) 
1(3) 
0(0) 
 
8(40) 
7(35) 
5(25) 
0(0) 
 
1(11) 
0(0) 
0(0) 
8(89) 
 
<0.0
01 
 
21(27
) 
41(53
) 
7(9) 
8(10) 
Risk factors for 
Giardiasis 
  Unwashed raw food 
  Unsafe  drinking  
water  
  Working-care of 
patients. 
  Previous giardiasis 
  Sexual contact with 
Giardia (anal sex) 
  Previous intestinal 
disease 
 
10 (100) 
9 (90) 
3 (30) 
1 (10) 
0 (0) 
 
1 (9.09) 
 
24 (67) 
19 (53) 
15 (42) 
1 (3) 
1 (3) 
 
0 (0) 
 
10 (59) 
14 (82) 
9 (47) 
0 (0) 
0(0) 
 
0 (0) 
 
4 (57) 
0 (0) 
6 (86) 
1 (13) 
0(0) 
 
1 (11) 
 
0.121 
<0.0
01 
0.124 
0.374 
0.778 
 
0.115 
 
48 
(69) 
42 
(60) 
33 
(46) 
3 (4) 
1 (1) 
 
2 (3) 
Symptoms associated 
with Giardiasis 
    Asymptomatic      
    Diarrhea 
    Fever 
    Abdominal pain 
    Vomiting 
    Aerophagia 
    Weight loss 
   Malaise 
    Anorexia 
 
 
4 (36) 
5(45) 
0 (0) 
6 (55) 
2 (18) 
4(36) 
3 (27) 
4(36) 
0 (0) 
 
 
1 (3) 
28 (76) 
13(35) 
30 (83) 
20 (54) 
26 (70) 
25 (69) 
24(65) 
5(14) 
 
 
3 (15) 
14(70) 
1(5) 
11 (55) 
3(15) 
11 (8) 
7 (41) 
6 (30) 
0 (0) 
 
 
0 (0) 
8 (89) 
0 (0) 
1 (13) 
1 (13) 
3 (38) 
3 (38) 
1 (13) 
0 (0) 
 
 
0.009 
0.149 
0.004 
0.001 
0.005 
0.122 
0.036 
0.01 
0.130 
 
 
8(11) 
55 
(71) 
14 
(18) 
48 
(64) 
26(34
) 
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44 
(59) 
38 
(53) 
35(46
) 
5 (7) 
Previous treatments 
   Antiparasitic     
   Antibiotic  
   Antidiarrhoeal  
 
0 (0) 
0 (0) 
1 (9) 
 
1 (3) 
9(24) 
4 (11) 
 
0 (0) 
3 (15) 
0 (0) 
 
1 (13) 
0 (0) 
1 (13) 
 
0.275 
0.133 
0.493 
 
2 (3) 
12(16
) 
6 (8) 
Other intestinal 
parasites 
   E. histolytica/dispar 
   Ascaris lumbricoides 
   Strongyloides 
stercoralis 
   Trichuris trichiura 
   Blastocystis hominis 
   Schistosoma spp.  
  Cryptosporidium spp. 
  Salmonella spp. 
 
0(0) 
0(0) 
3 (27) 
0(0) 
2 (18) 
0(0) 
0(0) 
0(0) 
 
3 (8) 
0(0) 
0(0) 
0(0) 
0(0) 
0(0) 
1 (3) 
1 (3) 
 
2 (10) 
2 (10) 
0 (0) 
1 (5) 
0(0) 
2 (10) 
0(0) 
0(0) 
 
0(0) 
0(0) 
0(0) 
0(0) 
1 (13) 
0(0) 
0(0) 
0(0) 
 
---- 
 
5 (6) 
2 (3) 
3 (4) 
1 (1) 
3 (4) 
2 (3) 
1 (1) 
1 (1) 
HIV 1 (9) 0 (0) 1 (6) 1 (13)  
0.377 
3 (5) 
IgA 
immunodeficiency 
--- 0 (0) 0 (0) 1 (100)  
0.018  
1 
(12.5) 
Number of risk 
factors: Median 
(IQR) 
2.5 (1) 2 (1) 2 (2.75) 2 (2) 0.142 --- 
Number of other 
intestinal parasites: 
Median (IQR) 
0 (4) 0 (0) 0 (0) 0 (0) 0.141  
*.  VFR: Visiting friends and relatives. Proportions are expressed as cases/total 
number of patients (percent). Numerical values are expressed as median 
(interquartile range –IQR). Continuous variables were analyzed by using an 
independent H Kruskal Wallis test, and categorical variables were analyzed with 
Monte Carlo and Fisher Exact test. 
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Table 2. Factors associated with refractory giardiasis  
 Refractory 
giardiasis 
Nº (%) 
Non refractory 
giardiasis 
Nº (%) 
OR (CI) p-
value 
Gender 
   Male 
   Female 
 
8/14  (57) 
6 /14 (43) 
 
29/57   (51)        
28/57   (49) 
 
1.28 (0.40-
4.18) 
 
0.770 
Age 
   <18 years 
   >18 years 
 
3/14   (21) 
11/14  (79) 
 
18/57  (32) 
39/57 (68) 
 
0.59 (0.16-
2.24) 
 
0.553 
Patients type 
  Migrant 
  Travelers 
   VFR* 
   No travel 
 
3/14  (21) 
11/14 (79) 
0 (0) 
0   (0) 
 
 
15/57 (26) 
29/57 (51) 
7/57 (12) 
6/57 (11) 
 
0.76 (0.20-
2.94) 
3.54 (0.95-
12.99) 
--- 
--- 
 
1 
0.185 
--- 
--- 
 
Continent 
  America 
  Asia 
  Africa 
  Europe 
 
1 /14         (7) 
10 /14      (71)  
3/14         (21) 
0 /14        (0) 
 
10 /57       (18) 
25 /57       (44) 
15/57        (26) 
7/57          (12)  
 
0.78 
(0.21-
3.01) 
3.2 (0.94-
10.80) 
0.76 
(0.20-
2.94) 
--- 
 
0.680 
0.079 
1 
--- 
Risk factors for 
Giardiasis 
    Raw food 
    Tap-water 
    Working-care of 
patients. 
    Previous  
giardiasis 
    Sexual contact 
with Giardia 
    Previous 
Intestinal disease 
 
4/12 (33) 
7/12 (58) 
4 /14 (29) 
2/13 (15) 
0/14 (0) 
0/14 (0) 
 
41/53 (77) 
32/54 (59) 
28/54 (52) 
1/54 (2) 
1/57 (2) 
2/57 (4) 
 
0.15 (0.04-
0.57) 
0.96 (0.28-
3.25) 
0.37 (0.1-
1.33) 
9.63 (0.82-
115) 
 --- 
--- 
 
0.005 
1 
0.143 
0.094 
--- 
--- 
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Symptoms of 
Giardia 
    Asymptomatic      
    Diarrhea 
    Fever 
    Abdominal pain 
    Vomiting 
    Weight loss 
    Malaise 
    Anorexia 
 
0/14  (0) 
13/14 (93) 
4/14 (29) 
9/13 (69) 
4/14 (29) 
8/13 (62) 
11/14 (79) 
3/14 (21) 
 
7/57 (12) 
39/57 (68) 
10/57 (18)  
36/57 (63) 
21/57 (37) 
28/55 (51) 
22/57 (39) 
2/57 (4) 
 
--- 
6 (0.73-
49.5) 
1.88 (0.49-
7.22) 
1.31 (0.36-
4.8) 
0.69 (0.19-
2.46) 
1.54 (0.45-
5.1) 
5.83 (1.46-
23.3) 
7.45 (1.12-
50.3) 
 
--- 
0.090 
0.453 
0.599 
0.757 
0.555 
0.014 
0.049 
Previous 
treatment 
  Antiparasitic  
  Antibiotic  
 
2/14 (14) 
5/14 (36) 
 
1/57 (2) 
6/57 (11) 
 
9.33 (0.78-
111.5) 
4.7 (1.19-
18.81) 
 
0.097 
0.033 
Assemblage 
 A  
AB 
B 
Not typable  
 
3/14 (21) 
0/14 (0) 
6/14 (43) 
4/14 (29) 
 
13/49 (27) 
1/49 (0) 
23/49 (47) 
13/49 (27) 
 
0.76 (0.20-
2.97) 
--- 
0.85 (0.27-
2.72) 
1.11 (0.31-
4.00) 
 
1 
--- 
1 
1 
*VFR:  Visiting friends and relatives. Proportions are expressed as 
cases/total number of patients (percent). Categorical variables were 
analyzed with Monte Carlo and Fisher Exact test. CI of OR were calculated 
by Woolf´s method 
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Table 3. Multivariate logistic regression model of the independent association of 
various variables with refractory giardiasis 
 
 OR CI  p-value  
Sex: Man    2.85      0.65-12.43        0.063 
Malaise: Yes     5.02     1.09-23.03        0.038 
Previous tto: Yes     6.19     1.41-27.14        
0.016 
Test Hosmer Lemeshow= 1.179, p =0.758; R2 Nagelkerke = 0.294 
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FIGURE LEGENDS 
 
Figure 1. Diagram about the clinical and treatment outcome of Giardia cases. 
 
 
 
